Jasper Therapeutics reported a net loss of $0.32 per share for the fourth quarter of 2025, a sharp improvement over the $0.81 loss per share that analysts had expected. The company’s full‑year 2025 loss per share was $3.95, down 20% from the $4.89 loss per share recorded in 2024. Revenue for the year remained $0.00, reflecting the company’s status as a clinical‑stage biopharma with no product sales. Operating cash burn for the nine months of 2025 was $55.3 million, leaving the company with $28.7 million in cash and cash equivalents and a runway of roughly eight to nine months at current spending levels.
The earnings beat was driven by disciplined cost management. While research and development expenses rose to $63.1 million from $55.8 million in 2024, the company avoided large one‑time charges and maintained tighter control over general and administrative costs, which helped narrow the net loss per share relative to expectations.
Comparing to the prior year, Jasper’s 2024 net loss totaled $71.3 million, with operating expenses of $76.2 million and a cash balance of $71.6 million. The decline in cash reserves to $28.7 million in 2025 underscores the company’s need for additional capital to sustain its clinical program and support future milestones.
Management emphasized its briquilimab program for chronic urticaria, noting that the company is preparing for a Phase 2b/3 study enrollment in the second half of 2026, contingent on capital availability. CEO Jeet Mahal highlighted the positive data from the BEACON study and the open‑label extension, stating that the results reaffirm briquilimab’s potential to deliver rapid and durable disease control.
Investor focus on the clinical data was evident in the market’s pre‑announcement reaction, with a 5.44% rise in pre‑market trading. The positive clinical updates appeared to outweigh the company’s modest financial performance, reflecting investor confidence in the therapeutic pipeline.
Headwinds remain significant. The company’s cash runway is limited, and future capital raises will be necessary to fund the planned Phase 2b/3 study and other development activities. The need for additional funding is a key risk factor that could impact the company’s ability to progress its clinical program.
Opportunities lie in the strong clinical data from the BEACON study and the potential expansion of briquilimab into asthma. These developments could broaden the company’s addressable market and provide a foundation for future revenue generation once the drug reaches the market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.